12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Insulin degludec: Phase IIIa data

The open-label, international Phase IIIa NN1250-3582 trial in 1,006 Type II diabetics showed that once-daily subcutaneous insulin degludec met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from baseline to week 52 (1.2% reduction for both). Degludec also led to a significantly lower...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >